Abstract
Objectives: Rapid muscle wasting occurs during acute respiratory failure, resulting in muscle weakness and functional impairments. This study examines survivors' body composition in the year after acute respiratory distress syndrome and tests associations of patient characteristics, hospital exposures, and survivors' strength and physical functioning with whole body percent lean mass. Design: Prospective cohort study with 6- and 12-month follow-up. Setting: National study enrolling patients from five study centers. Patients: Acute respiratory distress syndrome survivors (n = 120). Interventions: None. Measurements and Main Results: Lean and fat mass from dual energy x-ray absorptiometry. On average, survivors gained whole body total mass (+1.4 kg; 0.1-2.7) and fat mass (+1.2 kg; 0.2-2.2) and maintained lean mass (+0.2 kg; -0.4 to 0.8) between 6 and 12 months. Proportionally, percent fat mass increased and percent lean mass decreased for the whole body, trunk, and legs (p < 0.05). Greater whole body percent lean mass was associated with younger age, male sex, and lower baseline body mass index, but not other patient characteristics or ICU/hospital exposures. Greater percent lean mass was also significantly associated with gait speed and 6-minute walk distance, but not volitional strength or self-reported functional status. Conclusions: In the first year after acute respiratory distress syndrome, patients gained fat mass and maintained lean mass. We found no association of whole body percent lean mass with commonly hypothesized hospital risk factors. Direct measurement of body composition and performance-based functional measures may be helpful for understanding functional recovery in ICU survivors.
Original language | English |
---|---|
Pages (from-to) | 1238-1246 |
Number of pages | 9 |
Journal | Critical Care Medicine |
Volume | 46 |
Issue number | 8 |
DOIs | |
State | Published - 2018 |
Bibliographical note
Funding Information:Drs. Chan, Mourtzakis, and Needham conceived and designed the study. All authors contributed to the analysis plan and involved in the interpretation of study results. Drs. Dinglas, Hough, Ely, Morris, Hopkins, and Needham acquired the data, and Ms. Aronson Friedman performed all analyses. Drs. Chan and Mourtzakis drafted the article, and all authors critically revised it for important intellectual content and approved the final version to be submitted. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal). Supported, in part, by the National Heart, Lung, and Blood Institute (R24 HL111895, R01HL091760, R01HL091760-02S1, R01HL096504, Copyright © 2018 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Funding Information:
Drs. Chan, Aronson Friedman, Dinglas, Hough, Ely, Hopkins, and Needham received support for article research from the National Institutes of Health (NIH). Drs. Chan’s and Friedman’s institutions received funding from the National Heart, Lung, and Blood Institute. Drs. Hough’s, Ely’s, Hopkin’s, and Needham’s institutions received funding from the NIH. Dr. Ely’s institution also received funding from Veterans Administration funding, and he received funding from Orion, Abbott, and Pfizer. Dr. Needham’s institution also received funding from the National Health and Medical Research Council, Australia, the Gordon & Betty Moore Foundation, Reck Medical Devises, and Baxter Healthcare. The remaining authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: kchan10@jhu.edu
Funding Information:
Supported, in part, by the National Heart, Lung, and Blood Institute (R24 HL111895, R01HL091760, R01HL091760-02S1, R01HL096504, R01HL88045 and P050HL73994), the Johns Hopkins Institute for Clinical and Translational Research (UL1 TR 000424-06), and the Albuterol for the Treatment of ALI (ALTA), Early vs. Delayed Enteral Nutrition (EDEN), Omega Nutrition Supplement Trial (OMEGA), and Statins for Acutely Injured Lungs from Sepsis (SAILS) trials (contracts for sites participating in this study: HSN268200536170C, HHSN268200536171C, HHSN268200536173C, HHSN268200536174C, HSN268200536175C, and HHSN268200536179C).
Publisher Copyright:
Copyright © 2018 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Keywords
- Acute respiratory distress syndrome
- Anthropometry
- Dual energy x-ray absorptiometry
- Lean mass
- Longitudinal studies
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine